American Funds®

GROWTH FUNDS

®

229 Total Holdings:
As of 3/31/15 (updated quarterly, upon availability).
All Holdings: 1 - 15 of 229
Asset Type
Netflix, Inc. Equity 948,461 $395,214,214.00 2.66%
Thermo Fisher Scientific Inc. Equity 2,446,000 $328,595,640.00 2.22%
Hologic, Inc. Equity 8,315,450 $274,617,736.00 1.85%
Alexion Pharmaceuticals, Inc. Equity 1,512,900 $262,185,570.00 1.77%
Qorvo, Inc. Equity 3,239,474 $258,186,078.00 1.74%
Gilead Sciences, Inc. Equity 2,563,250 $251,531,723.00 1.7%
BioMarin Pharmaceutical Inc. Equity 1,959,550 $244,199,121.00 1.65%
Google Inc., Class C Equity 413,225 $226,447,300.00 1.53%
lululemon athletica inc. Equity 3,163,400 $202,520,868.00 1.37%
Amgen Inc. Equity 1,199,540 $191,746,469.00 1.29%
SoftBank Corp. Equity 3,103,000 $180,375,891.00 1.22%
Intuit Inc. Equity 1,647,200 $159,712,512.00 1.08%
Puma Biotechnology Inc Equity 657,740 $155,298,991.00 1.05%
Accenture PLC, Class A Equity 1,638,300 $153,492,327.00 1.03%
Kite Pharma, Inc. Equity 2,612,641 $150,697,133.00 1.02%
All Holdings: 1 - 15 of 229

Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.

Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.

  1. Excludes certain securities in initial period of acquisition.

Investing outside the United States involves risks, such as currency fluctuations, periods of illiquidity and price volatility, as more fully described in the prospectus. These risks may be heightened in connection with investments in developing countries.

For more information about the risks associated with each fund, go to its detailed fund information page or read the prospectus.